SARS-CoV-2 infection; Asthmatic; This case was received via Regulatory Authority (Reference number: GB-RA-ADR 27428126) on 03-Dec-2022 and was forwarded to Moderna on 03-Dec-2022.    This regulatory authority case was reported by a consumer and describes the occurrence of COVID-19 (SARS-CoV-2 infection) and ASTHMA (Asthmatic) in a 58-year-old female patient who received mRNA-1273 (Moderna CoviD-19 Vaccine) (batch no. 3004673) for COVID-19 prophylaxis.     Never had any breathing problems or asthma before took the booster injection. Unsure if patient had had symptoms associated with COVID-19.  The patient's past medical history included Steroid therapy (Taking regular steroid treatment (e.g., orally or rectally)).    On 22-Nov-2021, the patient received third dose of mRNA-1273 (Moderna CoviD-19 Vaccine) (unknown route) 1 dosage form. On 23-Nov-2021, the patient experienced ASTHMA (Asthmatic) (seriousness criterion medically significant). On 11-Mar-2022, the patient experienced COVID-19 (SARS-CoV-2 infection) (seriousness criterion medically significant). On 21-Mar-2022, COVID-19 (SARS-CoV-2 infection) had resolved. At the time of the report, ASTHMA (Asthmatic) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Mar-2022, SARS-CoV-2 test: Positive.     The action taken with mRNA-1273 (Moderna CoviD-19 Vaccine) (Unknown) was unknown.       Patient had 8 courses of antibiotics, five courses of steroids and now was on an inhaler.  Patient was not enrolled in clinical trial.  The details of any relevant investigations or tests conducted were CAT scan, X rays on chest and Blood tests. Company comment- This regulatory authority case concerns a 58-year-old female patient taking regular steroid treatment (for an unknown indication), who experienced the unexpected serious (medically significant) events of COVID-19 and asthma within the following day to approximately 3 months after a dose of mRNA-1273 vaccine, given as a booster dose of COVID vaccine schedule, was administered. SARS-CoV-2 test was positive. It was reported that patient never had any breathing problems or asthma before. She had 8 courses of antibiotics and five courses of steroids, and now is on an inhaler. Regular steroid treatment remains as a contributory risk factor for COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event´s seriousness was captured as reported. Sender's Comments: This regulatory authority case concerns a 58-year-old female patient taking regular steroid treatment (for an unknown indication), who experienced the unexpected serious (medically significant) events of COVID-19 and asthma within the following day to approximately 3 months after a dose of mRNA-1273 vaccine, given as a booster dose of COVID vaccine schedule, was administered. SARS-CoV-2 test was positive. It was reported that patient never had any breathing problems or asthma before. She had 8 courses of antibiotics and five courses of steroids, and now is on an inhaler. Regular steroid treatment remains as a contributory risk factor for COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event´s seriousness was captured as reported.